Last reviewed · How we verify
Vancomycin antibiotic powder
Vancomycin antibiotic powder is a glycopeptide antibiotic Small molecule drug developed by Major Extremity Trauma Research Consortium. It is currently in Phase 3 development for Treatment of serious or severe bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA).
Vancomycin works by inhibiting cell wall synthesis in bacteria, ultimately leading to cell lysis and death.
Vancomycin antibiotic powder is used to prevent infections such as Ventriculoperitoneal Shunt Infection, Surgical Site Infection, and Cerebrospinal Fluid Shunt Infection, particularly in pediatric patients. The exact mechanism of action of Vancomycin powder is unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vancomycin antibiotic powder |
|---|---|
| Sponsor | Major Extremity Trauma Research Consortium |
| Drug class | glycopeptide antibiotic |
| Target | cell wall precursors |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of cell wall precursors, preventing the incorporation of these precursors into the bacterial cell wall. This inhibition of cell wall synthesis ultimately leads to cell lysis and death.
Approved indications
- Treatment of serious or severe bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA)
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Anaphylaxis
Key clinical trials
- Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial (PHASE4)
- Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy (PHASE3)
- Acute Application of Antibiotic Powder in Open Fracture Wounds (PHASE4)
- Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA (PHASE3)
- Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty (PHASE1)
- Intramedullary Calcium Sulfate Antibiotic Depot (PHASE3)
- Combination Study of Antibiotics With Enzalutamide (PROMIZE) (PHASE1, PHASE2)
- Topical Vancomycin for Neurosurgery Wound Prophylaxis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin antibiotic powder CI brief — competitive landscape report
- Vancomycin antibiotic powder updates RSS · CI watch RSS
- Major Extremity Trauma Research Consortium portfolio CI
Frequently asked questions about Vancomycin antibiotic powder
What is Vancomycin antibiotic powder?
How does Vancomycin antibiotic powder work?
What is Vancomycin antibiotic powder used for?
Who makes Vancomycin antibiotic powder?
What drug class is Vancomycin antibiotic powder in?
What development phase is Vancomycin antibiotic powder in?
What are the side effects of Vancomycin antibiotic powder?
What does Vancomycin antibiotic powder target?
Related
- Drug class: All glycopeptide antibiotic drugs
- Target: All drugs targeting cell wall precursors
- Manufacturer: Major Extremity Trauma Research Consortium — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Treatment of serious or severe bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing